Danaher Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DHR research report →
About the company
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development.
- CEO
- Rainer Blair
- IPO
- 1978
- Employees
- 61,000
- HQ
- Washington, DC, US
Price Chart
- Market Cap
- $129.97B
- P/E
- 35.24
- P/S
- 5.25
- P/B
- 2.46
- EV/EBITDA
- 21.34
- Div Yield
- 0.74%
- Gross Margin
- 60.68%
- Op Margin
- 20.95%
- Net Margin
- 14.89%
- ROE
- 7.06%
- ROIC
- 5.73%
- Revenue
- $24.57B · 2.90%
- Net Income
- $3.61B · -7.31%
- EPS
- $5.07 · -4.88%
- Op Income
- $5.14B
- FCF YoY
- -0.68%
- 52W High
- $242.80
- 52W Low
- $160.93
- 50D MA
- $181.00
- 200D MA
- $205.14
- Beta
- 0.83
- Avg Volume
- 4.61M
Get TickerSpark's AI analysis on DHR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | FILLER LINDA | other | 680 |
| May 15, 26 | FILLER LINDA | other | 1,699 |
| May 15, 26 | Couchara Georgeann | other | 281 |
| May 15, 26 | Stevens Raymond C | other | 680 |
| May 15, 26 | Stevens Raymond C | other | 1,699 |
| May 15, 26 | SPOON ALAN G | other | 680 |
| May 15, 26 | SPOON ALAN G | other | 1,699 |
| May 15, 26 | Sanders A Shane | other | 680 |
| May 15, 26 | Sanders A Shane | other | 1,699 |
| May 15, 26 | List Teri | other | 680 |
Our DHR coverage
Recent articles, reports, and earnings notes.
Danaher (DHR): Recovery Momentum Meets Valuation Discipline
Danaher is emerging from a mixed-cycle recovery with improving bioprocessing orders, steady recurring revenue, and stronger EPS guidance. The stock looks attractive on a forward basis, but valuation still argues for buying on weakness.
The Best Healthcare Stocks Right Now (Updated June 2026)
These seven healthcare stocks combine recurring demand, identifiable franchises, and varying mixes of scale, profitability, and growth heading into June 2026.
Danaher Corporation (DHR) drops 5.4% after mixed Q1
Danaher Corporation (DHR) fell 5.4% after its latest earnings report, even with an EPS beat and a modest guidance raise. Investors focused on soft revenue, weak core growth, and mixed segment performance, especially in Diagnostics, which outweighed the company’s strong margins and cash flow.
Want a deeper read on DHR?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.